-

05:56:59 AM

Latest AXNX Stock Market News

AXNX - Axonics Inc

05/20/21 6:00 AM

Nasdaq : AXNX

Axonics® Receives FDA Approval Further Expanding MRI Labeling

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, has received FDA approval allowing the use of detachable extremity coils for patients undergoing 1.5T and 3.0T MRI scans.The

RHEA-AI

very positive

05/18/21 9:00 AM

Nasdaq : AXNX

Axonics® Announces CE Mark Approval for Implantable Sacral Neurostimulator that Significantly Extends Recharge Interval

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced European CE Mark approval of its second generation Axonics r-SNM ® implantable neurostimulator (INS) and

RHEA-AI

neutral

05/14/21 4:05 PM

Nasdaq : AXNX

Axonics® Announces Closing of Public Stock Offering and Full Exercise of Underwriters’ Option to Purchase Additional Stock

Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the closing of its public offering of 4,025,000 shares of common stock at the public offering

RHEA-AI

neutral

05/11/21 10:55 PM

Nasdaq : AXNX

Axonics® Announces Upsize and Pricing of Public Offering of Common Stock

Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, today announced the pricing of its public offering of 3,500,000 shares of its common stock at a public offering

RHEA-AI

neutral

05/11/21 4:17 PM

Nasdaq : AXNX

Axonics® Announces Proposed Public Offering of Common Stock

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today announced that it has commenced a proposed public offering of $150,000,000 in shares of its common stock. Axonics expects

RHEA-AI

neutral

05/06/21 4:01 PM

Nasdaq : AXNX

Axonics® Reports First Quarter 2021 Financial Results

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the first quarter ended March 31, 2021.“This quarter’s revenue result reflects growing

RHEA-AI

neutral

04/22/21 6:00 AM

Nasdaq : AXNX

Axonics® to Participate in the BofA Securities 2021 Virtual Healthcare Conference

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021.Axonics is

RHEA-AI

neutral

04/15/21 6:00 AM

Nasdaq : AXNX

Axonics® to Report First Quarter 2021 Financial Results on May 6, 2021

Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, will report first quarter 2021 financial results after the market closes on Thursday, May 6, 2021.In conjunction with the

RHEA-AI

neutral

03/03/21 6:00 AM

Nasdaq : AXNX

Axonics® to Participate in the Barclays Global Healthcare Conference

Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to participate in the virtual Barclays Global Healthcare Conference on March 10,

RHEA-AI

neutral

03/02/21 7:55 AM

Nasdaq : AXNX

Endotronix Appoints Industry Veteran Dan Dearen to Board of Directors

Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment of seasoned medical device industry executive Dan Dearen to its Board of Directors. Mr. Dearen

RHEA-AI

neutral

AXNX Data

industrySurgical and Medical Instrument Manufacturing
websitewww.axonicsmodulation.com
ceoRaymond Cohen
security nameAxonics Inc
issue typecs
sectorManufacturing
sic code3841
employees
tagsHealth Technology,Medical Specialties,Manufacturing,Surgical and Medical Instrument Manufacturing
address26 Technology Dr
address2
stateCalifornia
cityIrvine
zip92618-2380
countryUS
phone19493966322

AXNX Description:

Based in Irvine, Calif., Axonics has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for patients with bladder and bowel dysfunction, and through its acquisition of Bulkamid®, offers a best-in-class urethral bulking agent for women with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, with an additional 40 million adults estimated to suffer from fecal incontinence. Stress urinary incontinence affects an estimated 20 million women in the U.S. alone. Axonics' clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries.